Literature DB >> 19514970

Drug transporters: gatekeepers controlling access of xenobiotics to the cellular interior.

Lesley A Stanley1, Brian C Horsburgh, Jillian Ross, Nico Scheer, C Roland Wolf.   

Abstract

In this paper, we evaluate methodologies and null mouse models used to study drug transporter function in vitro and in vivo. P-glycoprotein and MRP null mice have been used to examine many aspects of xenobiotic distribution and bioavailability. Their advantage over conventional models is that they allow the exclusion of transporters from a particular process; however, they cannot be used to study the activity of the transporter that has been deleted. Use of humanized mice permits a logical progression from phenomena in wild-type mice via the effects of removing the mouse transporter to the consequences of replacing it with its human counterpart.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19514970     DOI: 10.1080/03602530802605040

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  5 in total

1.  Mechanisms for eliminating monoterpenes of sagebrush by specialist and generalist rabbits.

Authors:  Lisa A Shipley; Edward M Davis; Laura A Felicetti; Stuart McLean; Jennifer Sorensen Forbey
Journal:  J Chem Ecol       Date:  2012-10-05       Impact factor: 2.626

2.  Role of ribophorin II in the response to anticancer drugs in gastric cancer cell lines.

Authors:  Tein-Ming Yuan; Ruei-Yue Liang; Pin Ju Chueh; Show-Mei Chuang
Journal:  Oncol Lett       Date:  2015-01-27       Impact factor: 2.967

3.  Development and characterization of a novel mouse line humanized for the intestinal peptide transporter PEPT1.

Authors:  Yongjun Hu; Yehua Xie; Yuqing Wang; Xiaomei Chen; David E Smith
Journal:  Mol Pharm       Date:  2014-09-02       Impact factor: 4.939

4.  GeneGini: Assessment via the Gini Coefficient of Reference "Housekeeping" Genes and Diverse Human Transporter Expression Profiles.

Authors:  Steve O'Hagan; Marina Wright Muelas; Philip J Day; Emma Lundberg; Douglas B Kell
Journal:  Cell Syst       Date:  2018-02-07       Impact factor: 10.304

5.  RPN2 is effective biomarker to predict the outcome of combined chemotherapy docetaxel and cisplatin for advanced gastric cancer.

Authors:  Daisuke Fujimoto; Takanori Goi; Kenji Koneri; Yasuo Hirono
Journal:  Oncotarget       Date:  2018-03-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.